Immunization, Vaccines and Biologicals

SAGE Working Group on meningococcal vaccines (March 2010 to November 2011)

Terms of Reference

The Working Group is expected to review the evidence and prepare for a SAGE review, the necessary changes to be made to update the current meningitis position paper. The new position paper should make recommendation on the use of existing and upcoming conjugate vaccines including meningitis B, tetravalent meningitis ACWY, meningitis A and other and give updates on use of meningococcal polysaccharides vaccine.

The specific questions to be addressed:

  • Review data for recommendations regarding use of vaccines in outbreak settings
  • Review data to make recommendations on conjugate vaccine meningitis C and meningitis ACWY
  • Make recommendations on the use of conjugate vaccine meningitis A
  • Gather data on meningitis B Vaccine efficacy, safety and effectiveness in outbreaks
  • Review and make recommendation of the use of 1/5 fractioned dose of meningococcal polysaccharides vaccine in case of shortage of meningococcal polysaccharides vaccines.

Composition

SAGE Members

  • Jon Abramson, Chair of Working Group. Wake Forest University School of Medicine, United States of America
  • Zulfiqar Ahmed Bhutta, The Aga Khan University, Pakistan
  • David Durrheim, Hunter New England Area Health Service and Professor of Public Health, Australia
  • Juhani Eskola, National Institute for Health and Welfare, Finland

Experts

  • Florence Fermon, Médécins Sans Frontière, France
  • Keith Klugman, Emory University, US / National Institute for Communicable Diseases, South Africa
  • Nancy Messonnier, Centres for Disease Control, USA
  • Mary Ramsay, Health Protection Agency, UK
  • Samba Sow, Centre National d'Appui à la Lutte Contre la Maladie, Mali
  • Shao Zhujun, Institute for Communicable Disease Control and Prevention, People's Republic of China

WHO Secretariat

  • Carole Tevi- Benissan
  • Stéphane Hugonnet

DECLARATION OF INTERESTS FOR WHO EXPERTS

All Working Group members completed a declaration of interests. Four members reported relevant interests. All interests were assessed not to constitute a conflict of interest. It was concluded that all members could take part in full in all of the discussions. The reported relevant interests are summarized below.

Professor Zulfiqar Ahmed Bhutta
  • Received travel reimbursements from Sabin Institute for participation in two meetings as a member of the Pneumococcal Awareness Council of Experts. This interest was assessed as personal, non-specific and financially insignificant*.
  • His department received in March 2011 a research grant from Novartis Global Health Institute on a Phase II trail of Vi conjugate vaccination. This interest was assessed as non-personal, non-specific and financially significant*.
Professor Juhani Eskola:
  • Receives consultancy fees for membership in Novartis Data Safety Monitoring Board for typhoid vaccines. This interest was assessed as personal, non-specific and financially insignificant*.
  • Receives consultancy fees for membership in Novartis Data Safety Monitoring Board for meningococcal vaccines. This interest was assessed as personal, specific and financially insignificant*.
  • Received in 2009 consultancy fees for participation in Novartis Pneumococcal Vaccine Advisory Group. This interest was assessed as personal, non-specific and financially insignificant*.
  • His organization the National Institute for Health and Welfare of Finland has a large joint research programme with GlaxoSmithKline on pneumococcal vaccines. This interest was assessed as non-personal, non-specific and financially significant*.
Professor Keith Klugman
  • Received small consultancy fees from Novartis on meningococcal vaccines in Europe and the US, and from Aventis on vaccine development for developing countries between the years 2008 and 2009. These interests were assessed as personal, specific and financially insignificant*.
  • Supervised a study funded by Pfizer on non-meningococcus group B strains in South Africa in 2010. The funding was entirely directed to the research unit. This interest was assessed as specific, non-personal and financially insignificant*.

Mary Ramsay

  • Her sister-in-law is employed by GlaxoSmithKline as a project manager but does not work in the vaccine area. This interest was assessed as personal and non-specific*.

* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest has "financial significance" if the honoraria, consultancy fee or other received funding from any single company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one vaccine manufacturer or other vaccine-related company in excess of 1,000 USD would also constitute a “significant shareholding”.

Last updated: 18 November 2011

Share